Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q1 FY26 results · Apr–Jun 2025
Glenmark Pharmaceuticals reported revenue from operations of ₹3,264.44 crore (up 0.6% from Q1 FY25) and net profit of ₹46.97 crore (down 86.2% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,264.44 | 3,244.19 | +0.6% | 3,256.21 | +0.3% |
| Other income | 26.44 | 31.49 | −16.0% | 11.69 | +126.3% |
| Total income | 3,290.88 | 3,275.68 | +0.5% | 3,267.89 | +0.7% |
| Profit before tax | 95.58 | 462.33 | −79.3% | 7.97 | 12x |
| Net profit for the period | 46.97 | 340.24 | −86.2% | 4.38 | +971.5% |
| Attributable to shareholders of the company | 46.87 | — | — | 4.65 | +908.0% |
| EPS, basic (₹) | 1.66 | 12.06 | −86.2% | 0.16 | +937.5% |
| Net margin (%) | 1.4 | 10.5 | 0.1 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,394.93 | 2,329.54 | +2.8% | 2,009.49 | +19.2% |
| Other income | 69.33 | 55.65 | +24.6% | 88.45 | −21.6% |
| Total income | 2,464.26 | 2,385.18 | +3.3% | 2,097.95 | +17.5% |
| Profit before tax | 401.17 | 618.31 | −35.1% | 181.16 | +121.4% |
| Net profit for the period | 330.23 | 453.73 | −27.2% | 147.76 | +123.5% |
| EPS, basic (₹) | 11.70 | 16.08 | −27.2% | 5.24 | +123.3% |
| Net margin (%) | 13.8 | 19.5 | 7.4 |
Consolidated
- Filed with BSE
- 14 Aug 2025, 18:41 IST
- Board meeting
- 14 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Aug 2025, 18:41 IST
- Board meeting
- 14 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE